Friedelin

Friedelin is derived from the leaves of Maytenus ilicifolia (Mart). Friedelin is an orally active non-competitive inhibitor of CYP3A4, with IC₅₀ and K_i values of 10.79 μM and 6.16 μM, respectively. Friedelin is also a competitive inhibitor of CYP2E1, with IC₅₀ and K_i values of 22.54 μM and 18.02 μM, respectively. Friedelin can be used in research related to inflammation, neurological diseases, and metabolic disorders^[1][2][3][4]. IC50 & Target:IC50: 10.79 μM (CYP3A4), 22.54 μM (CYP2E1); Ki: 6.16 μM(CYP3A4), 18.02 μM(CYP2E1)^[1] In Vitro: Friedelin (40 μM, 24 hours) significantly inhibits NF-κB pathway activation and reduced inflammatory responses in tenocytes^[4]. In Vivo: Friedelin (40 mg/kg, p.o., single dose) exhibits potent anti-inflammatory activity in the carrageenan (HY-125474)-induced acute inflammation Wistar rat model^[2].
Friedelin (30 mg/kg, i.p., once daily, for 14 days) alleviats neuronal dysfunction and memory impairment in the scopolamine (HY-N0296)-induced neurodegeneration mouse model^[3].
Friedelin (40 μM, local injection near the right Achilles tendon, once weekly, for 4 weeks) prevents the progression of tendinopathy in the type I collagenase (HY-E70005A)-induced tendinopathy C57BL/6 mouse model^[4].